Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody

Lois M. Witters; Rakesh Kumar; Vernon Chinchilli; Allan Lipton

doi:10.1023/A:1005798224288

Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody

Lois M. Witters, Rakesh Kumar, Vernon Chinchilli, Allan Lipton

Research output: Contribution to journal › Article › peer-review

89 Scopus citations

Abstract

HER-2/neu overexpression has been associated with poor prognosis in human breast cancer. Many of these cancers are also ER-positive. A logical therapeutic approach for patients who are ER-positive and overexpress HER-2/neu may be to block both the ER and the HER-2/neu pathways. In our study, we used both the MTT tetrazolium dye assay and ³H-thymidine incorporation to measure the effects of the anti-estrogen Tamoxifen or the 4D5 anti-HER-2/neu antibody alone or in combination on the growth of BT474 human breast cancer cells which express ER and overexpress HER-2/neu. We found an enhanced inhibitory effect on cell proliferation with the combination of Tamoxifen and the antibody compared to that seen by either agent alone. This simultaneous interruption of both the ER and the HER-2/neu pathways may be relevant in the clinical treatment of patients who are both ER-positive and overexpress HER-2/neu.

Original language	English (US)
Pages (from-to)	1-5
Number of pages	5
Journal	Breast Cancer Research and Treatment
Volume	42
Issue number	1
DOIs	https://doi.org/10.1023/A:1005798224288
State	Published - Feb 11 1997

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1023/A:1005798224288

Cite this

@article{fc0d6bcb130a4b06ad003a383ffa9965,

title = "Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody",

abstract = "HER-2/neu overexpression has been associated with poor prognosis in human breast cancer. Many of these cancers are also ER-positive. A logical therapeutic approach for patients who are ER-positive and overexpress HER-2/neu may be to block both the ER and the HER-2/neu pathways. In our study, we used both the MTT tetrazolium dye assay and 3H-thymidine incorporation to measure the effects of the anti-estrogen Tamoxifen or the 4D5 anti-HER-2/neu antibody alone or in combination on the growth of BT474 human breast cancer cells which express ER and overexpress HER-2/neu. We found an enhanced inhibitory effect on cell proliferation with the combination of Tamoxifen and the antibody compared to that seen by either agent alone. This simultaneous interruption of both the ER and the HER-2/neu pathways may be relevant in the clinical treatment of patients who are both ER-positive and overexpress HER-2/neu.",

author = "Witters, {Lois M.} and Rakesh Kumar and Vernon Chinchilli and Allan Lipton",

year = "1997",

month = feb,

day = "11",

doi = "10.1023/A:1005798224288",

language = "English (US)",

volume = "42",

pages = "1--5",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer New York",

number = "1",

}

TY - JOUR

T1 - Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody

AU - Witters, Lois M.

AU - Kumar, Rakesh

AU - Chinchilli, Vernon

AU - Lipton, Allan

PY - 1997/2/11

Y1 - 1997/2/11

N2 - HER-2/neu overexpression has been associated with poor prognosis in human breast cancer. Many of these cancers are also ER-positive. A logical therapeutic approach for patients who are ER-positive and overexpress HER-2/neu may be to block both the ER and the HER-2/neu pathways. In our study, we used both the MTT tetrazolium dye assay and 3H-thymidine incorporation to measure the effects of the anti-estrogen Tamoxifen or the 4D5 anti-HER-2/neu antibody alone or in combination on the growth of BT474 human breast cancer cells which express ER and overexpress HER-2/neu. We found an enhanced inhibitory effect on cell proliferation with the combination of Tamoxifen and the antibody compared to that seen by either agent alone. This simultaneous interruption of both the ER and the HER-2/neu pathways may be relevant in the clinical treatment of patients who are both ER-positive and overexpress HER-2/neu.

AB - HER-2/neu overexpression has been associated with poor prognosis in human breast cancer. Many of these cancers are also ER-positive. A logical therapeutic approach for patients who are ER-positive and overexpress HER-2/neu may be to block both the ER and the HER-2/neu pathways. In our study, we used both the MTT tetrazolium dye assay and 3H-thymidine incorporation to measure the effects of the anti-estrogen Tamoxifen or the 4D5 anti-HER-2/neu antibody alone or in combination on the growth of BT474 human breast cancer cells which express ER and overexpress HER-2/neu. We found an enhanced inhibitory effect on cell proliferation with the combination of Tamoxifen and the antibody compared to that seen by either agent alone. This simultaneous interruption of both the ER and the HER-2/neu pathways may be relevant in the clinical treatment of patients who are both ER-positive and overexpress HER-2/neu.

UR - http://www.scopus.com/inward/record.url?scp=0031015394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031015394&partnerID=8YFLogxK

U2 - 10.1023/A:1005798224288

DO - 10.1023/A:1005798224288

M3 - Article

C2 - 9116313

AN - SCOPUS:0031015394

SN - 0167-6806

VL - 42

SP - 1

EP - 5

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 1

ER -

Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this